
-
At least 24 killed in Kashmir attack on tourists: Indian police source
-
Philippine typhoon victims remember day Pope Francis brought hope
-
IMF slashes global growth outlook on impact of Trump tariffs
-
BASF exits Xinjiang ventures after Uyghur abuse reports
-
Nordics, Lithuania plan joint purchase of combat vehicles
-
Gold hits record, stocks diverge as Trump fuels Fed fears
-
World could boost growth by reducing trade doubt: IMF chief economist
-
IMF slashes global growth outlook on impact of US tariffs
-
IMF slashes China growth forecasts as trade war deepens
-
Skipper Shanto leads Bangladesh fightback in Zimbabwe Test
-
US VP Vance says 'progress' in India trade talks
-
Ex-England star Youngs to retire from rugby
-
Black Ferns star Woodman-Wickliffe returning for World Cup
-
Kremlin warns against rushing Ukraine talks
-
Mbappe aiming for Copa del Rey final return: Ancelotti
-
US universities issue letter condemning Trump's 'political interference'
-
Pope Francis's unfulfilled wish: declaring PNG's first saint
-
Myanmar rebels prepare to hand key city back to junta, China says
-
Hamas team heads to Cairo for Gaza talks as Israel strikes kill 26
-
Pianist to perform London musical marathon
-
India's Bumrah, Mandhana win top Wisden cricket awards
-
Zurab Tsereteli, whose monumental works won over Russian elites, dies aged 91
-
Roche says will invest $50 bn in US, as tariff war uncertainty swells
-
Pope Francis's funeral set for Saturday, world leaders expected
-
US official asserts Trump's agenda in tariff-hit Southeast Asia
-
World leaders set to attend Francis's funeral as cardinals gather
-
Gold hits record, stocks mixed as Trump fuels Fed fears
-
Roche says will invest $50 bn in US over next five years
-
Fleeing Pakistan, Afghans rebuild from nothing
-
US Supreme Court to hear case against LGBTQ books in schools
-
Pistons snap NBA playoff skid, vintage Leonard leads Clippers
-
Migrants mourn pope who fought for their rights
-
Duplantis kicks off Diamond League amid Johnson-led changing landscape
-
Taliban change tune towards Afghan heritage sites
-
Kosovo's 'hidden Catholics' baptised as Pope Francis mourned
-
Global warming is a security threat and armies must adapt: experts
-
Can Europe's richest family turn Paris into a city of football rivals?
-
Climate campaigners praise a cool pope
-
As world mourns, cardinals prepare pope's funeral
-
US to impose new duties on solar imports from Southeast Asia
-
Draft NZ law seeks 'biological' definition of man, woman
-
Auto Shanghai to showcase electric competition at sector's new frontier
-
Tentative tree planting 'decades overdue' in sweltering Athens
-
Indonesia food plan risks 'world's largest' deforestation
-
Gold hits record, stocks slip as Trump fuels Fed fears
-
Trump helps enflame anti-LGBTQ feeling from Hungary to Romania
-
Woe is the pinata, a casualty of Trump trade war
-
'Like orphans': Argentina mourns loss of papal son
-
Trump tariffs torch chances of meeting with China's Xi
-
X rival Bluesky adds blue checks for trusted accounts

CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus
With the global CBD market expected to exceed $60 billion by 2030, and the mental wellness industry surging past $500 billion, CBD Life Sciences Inc. (OTC:CBDL) is strategically positioning itself at the center of two of the fastest-growing markets in modern health.
SCOTTSDALE, AZ / ACCESS Newswire / April 22, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) a leader in cannabinoid-driven health innovation - proudly announces the launch of its most anticipated product to date: a high-dosage 100MG Full Spectrum CBD Gummy, meticulously formulated to support mental health, daily focus, and emotional well-being.
Available in mouth-watering Crisp Green Apple and Wild Blueberry flavors, this isn't your average CBD gummy. It's a next-generation wellness tool - designed not only to relax the body but to sharpen the mind. Crafted with full-spectrum cannabinoids, these gummies are being positioned as a natural ally in the pursuit of mental clarity, balance, and daily productivity.
"Mental health isn't a trend - it's a global crisis. And people are tired of band-aid solutions," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "This product was built to empower people who want to feel better and function better - without the side effects of traditional pharmaceuticals. It's a powerful, natural alternative that speaks directly to the stress, anxiety, and attention struggles millions face every day."
Lab tested and verified with Certificates of Analysis (COAs), this 100MG gummy represents the company's deepest push yet into the lucrative mental wellness category. Unlike many low-dose competitors, CBDL's bold formulation is made for people who need real results - entrepreneurs, creatives, students, parents, and professionals looking to stay in control of their mood and mindset.
Early conversations with several wellness clinics and mental health centers are already in progress, exploring how this high-potency gummy could be integrated into patient routines. While no formal agreements have been made, the demand is clear: health professionals are actively seeking natural, high-quality, lab-verified CBD options to complement modern mental wellness protocols.
CBDL is rapidly building a portfolio that taps into high-value niches: from pain relief and nano-enhanced beverages to functional CBD coffee creamers and now, this cutting-edge product for mental clarity. The company's ability to stay ahead of trends and deliver results has attracted attention from both investors and the wellness industry.
"We're not trying to follow the market - we're reshaping it," Nelson added. "With this launch, we're doubling down on our belief that the future of wellness lies in functional, focused, and effective cannabinoid products."
This release is a bold statement to shareholders and the industry: CBD Life Sciences Inc. is serious about mental health. The company's momentum continues to build, and with this new launch, they're inviting wellness professionals, retail buyers, and everyday users to experience the next level of what CBD can offer.
The 100MG Mental Health Gummies are available now, with full lab reports and wholesale interest forms available on the company's website.
For product information, COAs, or wholesale inquiries, please visit www.thecbdvault.com.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (CBDL) is a leading innovator in the wellness and alternative health sector, specializing in high-quality CBD and functional mushroom products designed to enhance well-being. With a commitment to scientific research and consumer safety, CBDL continues to push the boundaries of holistic health solutions, creating opportunities for exponential growth in a rapidly evolving market.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: [email protected]
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
[email protected]
4802091720


SOURCE: CBD Life Sciences, Inc.
View the original press release on ACCESS Newswire
T.Ward--AMWN